Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study

Tolppanen, Anna‐Maija; Tiihonen, Miia; Taipale, Heidi; Koponen, Marjaana; Tanskanen, Antti; Lavikainen, Piia; Tiihonen, Jari; Hartikainen, Sirpa

doi:10.1007/s40266-018-0591-x

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 ). Details of each study included in the analysis are listed in Supplementary Table 1 [ [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] ].…”

Section: Resultsmentioning

confidence: 99%

Estradiol enhanced neuronal plasticity and ameliorated astrogliosis in human iPSC-derived neural models

Supakul,

Oyama,

Hatakeyama

et al. 2024

Regenerative Therapy

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Estradiol enhanced neuronal plasticity and ameliorated astrogliosis in human iPSC-derived neural models

Supakul,

Oyama,

Hatakeyama

et al. 2024

Regenerative Therapy

View full text Add to dashboard Cite

“…Although possibly beneficial if taken during a critical window near menopause, estrogens therapy (especially opposed compounds) initiated in later life may be associated with increased risk in A.D. Placebo-controlled trials reported an increased risk of the incidence of dementia in women who received a conjugated equine estrogen independently from the association of medroxyprogesterone acetate [ 40 ]. Tolppanen et al [ 41 ] did not find any differences in systemic estrogen use among Finnish women with AD than those without AD. The relation of AD risk to timing and type of hormone replacement deserves further study [ 42 ].…”

Section: The Role Of Estradiolmentioning

confidence: 99%

Impact of Testosterone on Alzheimer’s Disease

Bianchi

2022

World J Mens Health

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disease responsible for almost half of all dementia cases in the world and progressively increasing. The etiopathology includes heritability, genetic factors, aging, nutrition, but sex hormones play a relevant role. Animal models demonstrated that testosterone (T) exerted a neuroprotective effect reducing the production of amyloid-beta (Aβ), improving synaptic signaling, and counteracting neuronal death. This study aims to evaluate the impact of T deprivation and T administration in humans on the onset of dementia and AD. A search was conducted on MEDLINE and Scopus for the “androgen deprivation therapy” and “testosterone therapy” with “dementia” and “Alzheimer’s.” Studies lasting twenty years with low risk of bias, randomized clinical trial, and case-controlled studies were considered. Twelve articles on the effect of androgen deprivation therapy (ADT) and AD and seventeen on T therapy and AD were retrieved. Men with prostate cancer under ADT showed a higher incidence of dementia and AD. The effect of T administration in hypogonadal men with AD and cognitive impairment has evidenced some positive results. The majority of studies showed the T administration improved memory and cognition in AD while others did not find any benefit. Although some biases in the studies are evident, T therapy for AD patients may represent an essential clinical therapy to reduce dementia incidence and AD progression. However, more specific case-controlled trials on the effect of androgens therapy in men and women to reducing the onset of AD are necessary.

show abstract

Testosterone and Alzheimer’s disease

Kuznetsov

Khaidarova

Khabibullina

et al. 2022

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disease that causes dementia in half of the cases. Asthma is usually found in people over 65 years of age. The etiopathogenesis of the disease is multifactorial and includes genetic factors, nutritional disorders, mitochondrial dysfunction, oxidative stress, and aging. Sex hormones have an important influence on the development of AD, as evidenced by a higher incidence in women than in men. Considering the significant influence of T on the maintenance of normal brain function, the present study is aimed at evaluating the impact of androgen deprivation therapy (ADT), as well as testosterone therapy, on the risk of AD development and progression. Although there is some clinical inconsistency between studies, androgens have a significant effect on brain function and are beneficial for AD patients. Low levels of circulating androgens should be considered as a significant risk factor for the development of AD and memory loss. With a reduced level of T in the plasma of men, its administration improves cognitive performance and memory, treatment should be started at an early stage of the disease. In men and women with AD, androgens improve mental state and slow the progression of the disease, providing a protective effect. In the future, it is necessary to conduct studies on a large population, taking into account personality factors and a more specific approach to assessing cognitive functions and the causal relationship of T administration in AD.

show abstract

Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study

Cited by 3 publications

References 18 publications

Estradiol enhanced neuronal plasticity and ameliorated astrogliosis in human iPSC-derived neural models

Estradiol enhanced neuronal plasticity and ameliorated astrogliosis in human iPSC-derived neural models

Impact of Testosterone on Alzheimer’s Disease

Testosterone and Alzheimer’s disease

Contact Info

Product

Resources

About